(And ask Dr. Karen about it). Telebrutinin is an investigational, once-daily oral brain penetrant BTK inhibitor designed to target smoldering neuroinflammation in multiple sclerosis. Phase three trials showed it delayed disability progression by 31% in non-relapsing secondary progressive MS, though the FDA denied approval in 2025. Key side effects include potential liver enzyme elevation.